Insider filing · ELVN
Joseph P Lyssikatos
CHIEF SCIENTIFIC OFFICER
profile →
Enliven Therapeutics, Inc.
ELVN · Healthcare · 61 filings in 24 months
ticker →
Joseph P Lyssikatos sold $268K of Enliven Therapeutics (ELVN)
Executed Nov 19 2025, disclosed Nov 21 2025, 2 days later.
Value, as filed
$268K
12,008 sh × $22.30
Executed
Nov 19 2025
the trade date, as filed
Disclosed
Nov 21 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JLJoseph P Lyssikatos (CHIEF SCIENTIFIC OFFICER) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $3.5M of ELVN (132,500 sh across 4 lots, as filed), executed Jan 8.
The name
ELVNHealthcare · Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibito…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Joseph P Lyssikatos in ELVN
ELVNSALE
Enliven Therapeutics, Inc.
$145K5,000 sh × $29.04
Exec Feb 6
Filed Feb 10 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $535K
20,000 sh across 2 lots
Exec Jan 20
Filed Jan 22 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $3.5M
132,500 sh across 4 lots
Exec Jan 8
Filed Jan 12 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $276K
12,500 sh × $22.08
Exec Oct 20 2025
Filed Oct 22 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $150K
7,500 sh × $20.01
Exec Aug 21 2025
Filed Aug 21 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $265K
11,924 sh × $22.26
Exec Jul 21 2025
Filed Jul 23 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $268K
12,500 sh × $21.40
Exec Jun 20 2025
Filed Jun 24 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $150K
7,500 sh × $20.03
Exec Jun 3 2025
Filed Jun 5 2025 · 5:30 PM ET